Episode

E117: Inebilizumab for IgG4-RD (MITIGATE)

Podcast
The Evidence Based Rheumatology Podcast
Published
Dec 3, 2024
Duration seconds
775
Processing state
not_requested
Canonical source
https://msputman.podbean.com/e/e117-inebilizumab-for-igg4-rd-mitigate/
Audio
https://mcdn.podbean.com/mf/web/k396tk8uzna7wkbm/e117.mp3
JSON
/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e117-inebilizumab-for-igg4-rd-mitigate
Markdown
/podcast/the-evidence-based-rheumatology-podcast-1130175/e117-inebilizumab-for-igg4-rd-mitigate.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e117-inebilizumab-for-igg4-rd-mitigate/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e117-inebilizumab-for-igg4-rd-mitigate.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

New RCT in a new disease with a new drug! But is it as shiny as one would hope? Interesting discussion today about what a trial means, how it will affect practice, and how we could do better as a field. Happy holidays everyone!